Literature DB >> 34164726

Effect of type 2 diabetes on Gd-EOB-DTPA uptake into liver parenchyma: replication study in human subjects.

Soma Kumasaka1, Yuko Seki2, Yuka Kumasaka3, Yoshito Tsushima3.   

Abstract

PURPOSE: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is a contrast agent for magnetic resonance imaging (MRI), which specifically taken up by hepatocytes through organic anion-transporting polypeptides (OATPs). Previous research in mice has shown that type 2 diabetes is associated with reduced uptake of Gd-EOB-DTPA into the liver parenchyma, reflecting reduced expression of OATP. Since considerable differences in OATP expression exist between mice and humans, human studies are necessary to clarify the effect of diabetes to Gd-EOB-DTPA uptake. The purpose of this study was to validate the effect of diabetes to Gd-EOB-DTPA liver uptake by a confirmatory study in humans.
METHODS: Patients who underwent Gd-EOB-DTPA-enhanced MRI were retrospectively reviewed and divided into two groups: severe or uncontrolled diabetic group (patients with insulin therapy and/or HbA1c ≥ 8.4%) and the control group. Liver-to-spleen ratio (LSR) and relative enhancement of the liver (REL) were calculated to represent Gd-EOB-DTPA liver uptake.
RESULTS: A total of 94 patients fulfilled the criteria. The severe or uncontrolled diabetic group (n = 15) showed significantly lower LSR (1.74 ± 0.26 vs. 1.98 ± 0.31, p = 0.007) and REL (0.69 ± 0.23 vs. 0.87 ± 0.31, p = 0.005), compared to the control group (n = 79).
CONCLUSION: Our study revealed decreased uptake of Gd-EOB-DTPA into liver parenchyma in the severe or uncontrolled diabetic patients. Further studies to determine the impact of the reduced liver enhancement on clinical diagnostic practice will be needed.

Entities:  

Keywords:  Diabetes; Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA); Liver enhancement; Magnetic resonance imaging (MRI)

Year:  2021        PMID: 34164726     DOI: 10.1007/s00261-021-03184-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  37 in total

1.  Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.

Authors:  T Abe; M Kakyo; T Tokui; R Nakagomi; T Nishio; D Nakai; H Nomura; M Unno; M Suzuki; T Naitoh; S Matsuno; H Yawo
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

2.  Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.

Authors:  T J Vogl; S Kümmel; R Hammerstingl; M Schellenbeck; G Schumacher; T Balzer; W Schwarz; P K Müller; W O Bechstein; M G Mack; O Söllner; R Felix
Journal:  Radiology       Date:  1996-07       Impact factor: 11.105

Review 3.  P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.

Authors:  Caroline A Lee; Jack A Cook; Eric L Reyner; Dennis A Smith
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-05       Impact factor: 4.481

4.  Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

Authors:  Masaru Hirano; Kazuya Maeda; Yoshihisa Shitara; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-04-04       Impact factor: 3.922

Review 5.  Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.

Authors:  Nicola F Smith; William D Figg; Alex Sparreboom
Journal:  Expert Opin Drug Metab Toxicol       Date:  2005-10       Impact factor: 4.481

6.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

Review 7.  Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.

Authors:  Bruno Hagenbuch; Peter J Meier
Journal:  Pflugers Arch       Date:  2003-10-25       Impact factor: 3.657

Review 8.  P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations.

Authors:  Adorjan Aszalos
Journal:  Arch Pharm Res       Date:  2004-02       Impact factor: 4.946

9.  Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.

Authors:  P Reimer; E J Rummeny; K Shamsi; T Balzer; H E Daldrup; B Tombach; T Hesse; T Berns; P E Peters
Journal:  Radiology       Date:  1996-04       Impact factor: 11.105

Review 10.  The superfamily of organic anion transporting polypeptides.

Authors:  B Hagenbuch; P J Meier
Journal:  Biochim Biophys Acta       Date:  2003-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.